X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (41) 41
humans (40) 40
male (32) 32
middle aged (28) 28
aged (27) 27
female (27) 27
hematology (23) 23
adult (15) 15
prognosis (14) 14
treatment outcome (13) 13
multiple myeloma - drug therapy (12) 12
bortezomib (11) 11
disease-free survival (11) 11
oncology (11) 11
stem-cell transplantation (11) 11
thalidomide - administration & dosage (11) 11
antineoplastic combined chemotherapy protocols - therapeutic use (9) 9
lenalidomide (9) 9
multiple myeloma - mortality (9) 9
retrospective studies (9) 9
aged, 80 and over (8) 8
diagnosis (8) 8
elderly-patients (8) 8
multiple myeloma (8) 8
risk factors (8) 8
transplantation (8) 8
boronic acids - administration & dosage (7) 7
hematology, oncology and palliative medicine (7) 7
medicine & public health (7) 7
pyrazines - administration & dosage (7) 7
therapy (7) 7
hematopoietic stem cell transplantation (6) 6
kaplan-meier estimate (6) 6
mortality (6) 6
multivariate analysis (6) 6
recurrence (6) 6
survival (6) 6
thalidomide (6) 6
thalidomide - analogs & derivatives (6) 6
abridged index medicus (5) 5
acute disease (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
chemotherapy (5) 5
dexamethasone (5) 5
follow-up studies (5) 5
immunology (5) 5
internal medicine (5) 5
italy - epidemiology (5) 5
melphalan - administration & dosage (5) 5
prednisone - administration & dosage (5) 5
prednisone plus thalidomide (5) 5
risk (5) 5
thalidomide - therapeutic use (5) 5
analysis (4) 4
antineoplastic agents - administration & dosage (4) 4
bone-marrow-transplantation (4) 4
boronic acids - adverse effects (4) 4
care and treatment (4) 4
criteria (4) 4
hematopoietic stem cells (4) 4
incidence (4) 4
initial treatment (4) 4
melphalan - adverse effects (4) 4
metaanalysis (4) 4
multiple myeloma - diagnosis (4) 4
multiple myeloma - therapy (4) 4
multiple-myeloma (4) 4
patients (4) 4
prednisone - adverse effects (4) 4
prognostic-factors (4) 4
pulmonary embolism (4) 4
pyrazines - adverse effects (4) 4
research (4) 4
survival analysis (4) 4
thalidomide - adverse effects (4) 4
transplantation, autologous (4) 4
versus-host-disease (4) 4
young adult (4) 4
antineoplastic agents - therapeutic use (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
autologous transplantation (3) 3
blood (3) 3
bortezomib-melphalan-prednisone (3) 3
cancer (3) 3
case report (3) 3
child (3) 3
clinical-trials (3) 3
diseases of the blood and blood-forming organs (3) 3
graft vs host disease - immunology (3) 3
guidelines (3) 3
in situ hybridization, fluorescence (3) 3
infectious diseases (3) 3
lenalidomide plus dexamethasone (3) 3
leukemia (3) 3
lymphoma (3) 3
maintenance therapy (3) 3
medicine, general & internal (3) 3
multiple myeloma - complications (3) 3
oral melphalan (3) 3
predictive value of tests (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 12/2010, Volume 28, Issue 34, pp. 5101 - 5109
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2014, Volume 32, Issue 7, pp. 634 - 640
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2011, Volume 29, Issue 8, pp. 986 - 993
Purpose In patients with myeloma, thalidomide significantly improves outcomes but increases the risk of thromboembolic events. In this randomized, open-label,... 
LOW-DOSE WARFARIN | DEXAMETHASONE | THERAPY | VENOUS THROMBOEMBOLISM | ONCOLOGY | DEEP-VEIN THROMBOSIS | PREDNISONE PLUS THALIDOMIDE | BORTEZOMIB | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | MELPHALAN | Multiple Myeloma - mortality | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Warfarin - adverse effects | Male | Antineoplastic Agents - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Warfarin - therapeutic use | Fibrinolytic Agents - adverse effects | Multiple Myeloma - drug therapy | Thromboembolism - prevention & control | Time Factors | Aspirin - adverse effects | Fibrinolytic Agents - therapeutic use | Cardiovascular Diseases - mortality | Female | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Cardiovascular Diseases - etiology | Risk Assessment | Multiple Myeloma - complications | Risk Factors | Anticoagulants - therapeutic use | Treatment Outcome | Thromboembolism - etiology | Thromboembolism - mortality | Thalidomide - administration & dosage | Anticoagulants - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Italy | Aged | Hemorrhage - chemically induced | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2015, Volume 33, Issue 30, pp. 3459 - 3466
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 9/2013, Volume 57, Issue 6, pp. 794 - 802
Background. The objective of this analysis was to investigate prognostic factors that influence the outcome of Epstein-Barr virus (EBV)—related posttransplant... 
Health outcomes | Immunosuppression | Lymphoproliferative disorders | Mortality | Predisposing factors | Viral diseases | Transplantation | Graft vs host disease | Epstein Barr virus infections | ARTICLES AND COMMENTARIES | Blood | hematopoietic stem cell transplantation | risk factors | Epstein-Barr virus | post-transplant lymphoproliferative disorder | prognostic model | INFECTIOUS DISEASES | MANAGEMENT | PROGNOSTIC-FACTORS | LOAD | SCT | MICROBIOLOGY | IMMUNOLOGY | RECIPIENTS | VERSUS-HOST-DISEASE | REACTIVATION | LYMPHOMA | PTLD | LYMPHOCYTES | Prognosis | Humans | Middle Aged | Child, Preschool | Infant | Epstein-Barr Virus Infections - surgery | Viral Load | Herpesvirus 4, Human - isolation & purification | Adult | Retrospective Studies | Child | Epstein-Barr Virus Infections - epidemiology | Lymphoproliferative Disorders - surgery | Epstein-Barr Virus Infections - virology | Lymphoproliferative Disorders - virology | Risk Factors | Kaplan-Meier Estimate | Europe - epidemiology | Hematopoietic Stem Cell Transplantation | Rituximab | Epstein-Barr Virus Infections - drug therapy | Lymphoproliferative Disorders - epidemiology | DNA, Viral - blood | Adolescent | Lymphoproliferative Disorders - drug therapy | Aged | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Immunologic Factors - therapeutic use | Prescription drugs | Hematology | Stem cells | Drug therapy | Multivariate analysis | Blood diseases | Risk factors | Clinical outcomes | Index Medicus
Journal Article
Journal of Hematology and Oncology, ISSN 1756-8722, 01/2019, Volume 12, Issue 1, pp. 4 - 4
Journal Article
Blood, ISSN 0006-4971, 07/2012, Volume 120, Issue 1, pp. 9 - 19
Journal Article
Blood, ISSN 0006-4971, 12/2010, Volume 116, Issue 23, pp. 4745 - 4753
Journal Article
Journal Article
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2012, Volume 18, Issue 4, pp. 617 - 626
Allogeneic stem cell transplantation (allo-SCT) using reduced-intensity conditioning (RIC) is a feasible procedure in selected patients with relapsed multiple... 
Hematology, Oncology and Palliative Medicine | Novel drugs | Reduced-intensity regimens | Donor versus no-donor analysis | MOLECULAR REMISSION | PROGNOSTIC-FACTORS | BONE-MARROW-TRANSPLANTATION | LENALIDOMIDE PLUS DEXAMETHASONE | AUTOLOGOUS TRANSPLANTATION | RISK | EUROPEAN GROUP | BORTEZOMIB | IMMUNOLOGY | VERSUS-HOST-DISEASE | TRANSPLANTATION | THERAPY | HEMATOLOGY | Myeloablative Agonists - therapeutic use | Recurrence | Multiple Myeloma - mortality | Humans | Middle Aged | Pyrazines - administration & dosage | Salvage Therapy | Multiple Myeloma - immunology | Transplantation, Autologous | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Antineoplastic Agents - administration & dosage | Boronic Acids - therapeutic use | Graft vs Host Disease - immunology | Multiple Myeloma - therapy | Adult | Retrospective Studies | Boronic Acids - administration & dosage | Bortezomib | Histocompatibility Testing | Hematopoietic Stem Cell Transplantation | Thalidomide - administration & dosage | Disease-Free Survival | Myeloablative Agonists - administration & dosage | Graft vs Host Disease - prevention & control | Aged | Thalidomide - therapeutic use | Tissue Donors | Transplantation Conditioning | Comorbidity | Analysis | Multiple myeloma | Stem cells | Transplantation of organs, tissues, etc | Development and progression | Transplantation | Chromosomes | Index Medicus
Journal Article
Journal Article